Edition:
United States

Medicines Co (MDCO.OQ)

MDCO.OQ on NASDAQ Stock Exchange Global Select Market

31.07USD
23 Feb 2018
Change (% chg)

$1.24 (+4.16%)
Prev Close
$29.83
Open
$29.97
Day's High
$31.42
Day's Low
$29.32
Volume
488,882
Avg. Vol
448,657
52-wk High
$55.94
52-wk Low
$24.45

Chart for

About

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin... (more)

Overall

Beta: 0.71
Market Cap(Mil.): $2,264.92
Shares Outstanding(Mil.): 72.90
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-The Medicines Q4 GAAP Loss Per Share $2.19 From Continuing Operations

* THE MEDICINES COMPANY REPORTS FOURTH-QUARTER AND FULL-YEAR 2017 BUSINESS AND FINANCIAL RESULTS

Feb 21 2018

BRIEF-The Medicines Company Reaches Enrollment Target For Orion-9 Ahead Of Schedule

* THE MEDICINES COMPANY REACHES ENROLLMENT TARGET FOR ORION-9 AHEAD OF SCHEDULE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Feb 20 2018

BRIEF-Medicines Co Reports 10.6 Pct Passive Stake In Melinta Therapeutics

* THE MEDICINES COMPANY REPORTS 10.6 PERCENT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN. 5, 2018 - SEC FILING‍​ Source text: (http://bit.ly/2muRQBT) Further company coverage:

Jan 11 2018

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

Nov 29 2017

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

Nov 29 2017

BRIEF-Medicines Co names Fred Eshelman executive chairman

* The Medicines Company names Dr. Fred Eshelman as executive chairman; appoints Geno Germano to its board of directors

Nov 15 2017

BRIEF-SymBio Pharmaceuticals says arbitration against The Medicines Company

* Says co initiated an arbitration against The Medicines Company (MDCO) on Oct. 11, under the rules of International Chamber of Commerce, seeking damages arising out of MDCO's repudiation of the license agreement entered into between the co and MDCO on October 5, 2015, for the exclusive rights to develop and commercialize the patient-controlled pain management drug "SyB P-1501" (or "IONSYS") in Japan

Nov 13 2017

BRIEF-The Medicines Co and Alnylam Pharmaceuticals to start phase III clinical trials of inclisiran

* The Medicines Company and Alnylam Pharmaceuticals announce initiation of phase III clinical trials of inclisiran

Nov 06 2017

BRIEF-The Medicines Company reports third-quarter 2017 business and financial results

* The Medicines Company reports third-quarter 2017 business and financial results

Oct 25 2017

Alnylam's RNAi drug succeeds in key study, shares soar

Alnylam Pharmaceuticals Inc's RNAi-based drug that targets a rare genetic disease met the main goal of a key study, in a breakthrough for the new class of medicines that works by blocking disease-causing proteins.

Sep 20 2017

Earnings vs. Estimates